Shots:
- The Akeso‘s global P-III (HARMONi-6/AK112-306) trial assessed ivonescimab + CT vs Tevimbra + CT to treat pts (n=532) with 1L sqNSCLC, meeting its 2EP of improved OS
- As of Feb 27, 2026 (mFU: 21.36mos.), ivonescimab + CT reduced the death risk by 34%(mOS: 27.9 vs 23.7mos.), with 12 and 24mos. OS rate of 78.9% vs 72.2% and 64.7% vs 48.6%, respectively; OS benefit was consistent regardless of PD-L1 status & metastatic burden
- At interim analysis, the trial showed improved PFS (mPFS: 11.1 vs 6.9mos.). Subsequent therapies were less common in the therapy arm, incl. immunotherapy (13.9% vs. 19.2%), targeted therapy (12.4% vs. 17.3%), ADCs (4.5% vs. 5.6%), & proportions participating in other trials (0.8% vs 2.3%)
Ref: Prnewswire | Image: Akeso | Press Release
Related News: Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
